Mylan NV(NASDAQ:MYL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $2.56B. Analysts estimated a revenue of $2.57B. Earnings per share were $1.16. Analysts had estimated an EPS of $1.14.
Mylan NV (MYL) made into the market gainers list on Wednesdays trading session with the shares advancing 0.76% or 0.37 points. Due to strong positive momentum, the stock ended at $48.9, which is also near the day’s high of $49.16. The stock began the session at $48.76 and the volume stood at 25,91,780 shares. The 52-week high of the shares is $56.44 and the 52 week low is $37.59. The company has a current market capitalization of $26,157 M and it has 53,49,11,500 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Joseph C Md Maroon (director) purchased 1,670 shares at $44.95 per share price.Also, On May 25, 2016, Robert J Cindrich (director) purchased 1,190 shares at $42.47 per share price.On May 16, 2016, Melina E Higgins (director) purchased 19,900 shares at $38.68 per share price, according to the Form-4 filing with the securities and exchange commission.
Mylan N.V. formerly Mylan Inc. is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively North America); Europe the Middle East and Africa (collectively EMEA); and India Australia Japan and New Zealand (collectively Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India) which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.